SL1002
Asset
Neurolytic formulation providing prolonged pain relief or spasticity reduction
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- Not known
- 2
- Indications
- 0
- Trials
- 1
- Developer
Indications
2Chronic pain related to osteoarthritis of the knee
Phase 3, prnewswire.com, 8 Oct 2026
Spasticity
Phase 2, prnewswire.com, 8 Oct 2026
In the full profile
- Owner and partners1
Every asset’s record: target, stage, trials and the evidence behind it.